Open AccessNeuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma
Author(s) -
Shunpei Satoh,
Atsushi Takatori,
Atsushi Ogura,
Kenichi Kohashi,
Ryota Souzaki,
Yoshiaki Kinoshita,
Tomoaki Taguchi,
Md. Shamim Hossain,
Miki Ohira,
Yohko Nakamura,
Akira Nakagawara
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep32682
Subject(s) - ectodomain , anaplastic lymphoma kinase , cancer research , biology , neuroblastoma , tyrosine kinase , kinase , signal transduction , transmembrane protein , receptor tyrosine kinase , leucine rich repeat , nonsynonymous substitution , anaplastic large cell lymphoma , microbiology and biotechnology , receptor , lymphoma , genetics , medicine , gene , cell culture , immunology , genome , pleural effusion , malignant pleural effusion
In neuroblastoma (NB), one of the most common paediatric solid tumours, activation of anaplastic lymphoma kinase (ALK) is often associated with poor outcomes. Although genetic studies have identified copy number alteration and nonsynonymous mutations of ALK , the regulatory mechanism of ALK signalling at protein levels is largely elusive. Neuronal leucine-rich repeat 1 (NLRR1) is a type 1 transmembrane protein that is highly expressed in unfavourable NB and potentially influences receptor tyrosine kinase signalling. Here, we showed that NLRR1 and ALK exhibited a mutually exclusive expression pattern in primary NB tissues by immunohistochemistry. Moreover, dorsal root ganglia of Nlrr1 +/+ and Nlrr1 −/− mice displayed the opposite expression patterns of Nlrr1 and Alk. Of interest, NLRR1 physically interacted with ALK in vitro through its extracellular region. Notably, the NLRR1 ectodomain impaired ALK phosphorylation and proliferation of ALK-mutated NB cells. A newly identified cleavage of the NLRR1 ectodomain also supported NLRR1-mediated ALK signal regulation in trans . Thus, we conclude that NLRR1 appears to be an extracellular negative regulator of ALK signalling in NB and neuronal development. Our findings may be beneficial to comprehend NB heterogeneity and to develop a novel therapy against unfavourable NB.